A Japanese government panel has approved the world's first clinical research using human induced pluripotent stem cells, officials said. The panel of the country's Health Ministry has issued approval for governmental scientific research institute Riken and the Foundation for Biomedical Research and Innovation to conduct a clinical research plan to use iPS cells for retinal regeneration, Kyodo News reported Wednesday. Kyoto University Professor Shinya Yamanaka co-won the 2012 Nobel Prize in physiology or medicine for his development of iPS cells, which can grow into any type of human body tissue and are seen as candidates for regenerative medicine and drug development. The clinical research team will try to develop treatment techniques using iPS cells to cure age-related macular degeneration, a condition that can cause sudden vision loss due to retinal damage. The team said it would extract skin cells from several patients, create iPS cells from them, develop them into pigment epithelium of the retina and transplant them into the patients' retinas. The researchers said they would attempt the transplants next year.
GMT 17:42 2018 Wednesday ,31 October
Launch of cargo spacecraft Progress MS-10 to ISS set for 16 NovemberGMT 14:18 2018 Saturday ,27 October
First launch of Soyuz-FG booster after Oct 11 incident scheduled on 16 NovGMT 16:58 2018 Monday ,22 October
Report on Soyuz-FG vehicle malfunction to be approved on 30 OctoberGMT 22:05 2018 Friday ,19 October
NASA chief believes human mission to Mars should become international projectGMT 16:31 2018 Monday ,15 October
Roscosmos chief to inform NASA and ESA on probe into Soyuz booster incidentGMT 18:09 2018 Thursday ,11 October
Russia to provide NASA with full information on Soyuz emergency landingGMT 16:09 2018 Thursday ,11 October
President Putin to receive report on aborted Soyuz space launch to ISSGMT 10:49 2018 Friday ,19 January
Amazon narrows list of 'HQ2' candidates to 20Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor